IRON
Disc Medicine Inc

337
Mkt Cap
$3.13B
Volume
272,440.00
52W High
$95.95
52W Low
$30.82
PE Ratio
-18.74
IRON Fundamentals
Price
$83.85
Prev Close
$87.00
Open
$87.00
50D MA
$71.70
Beta
1.02
Avg. Volume
577,169.83
EPS (Annual)
-$3.96
P/B
5.12
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Y Intercept Hong Kong Ltd Acquires New Position in Disc Medicine, Inc. $IRON
Y Intercept Hong Kong Ltd bought a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now?
Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·12d ago
News Placeholder
Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?
The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·17d ago
News Placeholder
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.
Stocktwits·23d ago
News Placeholder
Raymond James bullish on biotech firms on favorable valuation
Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”
investing.com·5mo ago
News Placeholder
Disc Medicine (NASDAQ:IRON) Given "Outperform" Rating at Wedbush
Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price...
Ticker Report·2y ago
News Placeholder
FY2024 Earnings Estimate for Disc Medicine, Inc. Issued By Wedbush (NASDAQ:IRON)
Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Monday, April 1st. Wedbush analyst D...
Ticker Report·2y ago
News Placeholder
Leerink Partnrs Comments on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)
Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings per share estimates for shares of Disc Medicine in a report issued on Monday, April...
Ticker Report·2y ago
News Placeholder
Raymond James Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)
Disc Medicine (NASDAQ:IRON - Get Free Report)s stock had its "outperform" rating reaffirmed by analysts at Raymond James in a report issued on Monday, Marketbeat Ratings reports. They...
Zolmax·2y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...
TipRanks Financial Blog·2y ago

Latest IRON News

View

Advertisement|Remove ads.

Advertisement|Remove ads.